Chiesi Farmaceutici S.p.a.

Lilian Alcaraz

Elisabetta Armani

Christopher Hurley

Andrew Peter Cridland

Andrew Stephen Robert Jennings

Terry Aaron Panchal

Nicholas Charles Ray

Monique Bodil Van Niel

Carmelida Capaldi

Jonathan Mark Sutton

Robert Andrew Heald

Chi-Kit Woo

This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.

Pyrimidinone compounds which are HNE inhibitors

Pyrimidone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and condition in which HNE is implicated.

Pyrimidinone compounds as human neutrophil elastase inhibitors

Heterocyclic compounds and salts according to formula (I), which are pyrimidinone derivatives, described herein exhibit human neutrophil elastase inhibitory properties, and useful for treating diseases or conditions in which HNE is implicated.

Compounds

Mitogen activated protein kinase (MAPK) inhibitors disclosed herein are useful for the treatment of diseases of the respiratory tract, such as chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, and airways disease that is associated with pulmonary hypertension.

Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38&#x2014;MAP kinase inhibitors

Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R, W, A, Y and Rare as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Kinase inhibitors

Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Pyrimidinone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HINE is implicated.

This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Compounds of formula (I): wherein R, W, A, Y, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Growing community of inventors

Harlow, United Kingdom

Lilian Alcaraz